Primary Care Management of Lower Urinary Tract Symptoms in Men (PriMUS)
Lower Urinary Tract Symptoms
About this trial
This is an interventional diagnostic trial for Lower Urinary Tract Symptoms focused on measuring Lower Urinary Tract Symptoms, Primary Care, Urology
Eligibility Criteria
Inclusion Criteria:
- Men aged 16 years and over.
- Men who present to their GP with a complaint of one or more bothersome lower urinary tract symptoms (LUTS)#
- Men able and willing to give informed consent for participation in study
Men able and willing to undergo all index tests and reference test, and complete study documentation.
- This would include men on current treatment, but who are still symptomatic
Exclusion criteria
- Men with neurological disease or injury affecting lower urinary tract function
- Men with LUTS considered secondary to current or past invasive treatment or radiotherapy for pelvic disease
- Men with other contraindications to urodynamics e.g. Heart valve or joint replacement surgery within the last 3 months, immunocompromised/immunosuppressed.
- Men with indwelling urinary catheters or who carry out intermittent self-catheterisation
Men whose initial assessment suggests that clinical findings are suggestive of possible:
- prostate or bladder cancer*
- recurrent or persistent symptomatic UTI**
- retention e.g. palpable bladder after voiding'
Men unable to consent in English or Welsh where a suitable translator is not available. This is a multi-centre study based in primary care, and we cannot guarantee translation facilities at all sites
According to standard NHS cancer pathways. If later deemed unlikely, then eligible for study participation.
- If UTI successfully treated but LUTS remain, then eligible for study
Sites / Locations
- Cardiff UniversityRecruiting
Arms of the Study
Arm 1
Other
Development of Clinical Decision Support Tool
All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.